期刊
ARCHIV DER PHARMAZIE
卷 353, 期 11, 页码 -出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/ardp.202000130
关键词
angiogenesis inhibitor; kinase inhibitor; LASSBio-2027; N-acylhydrazone; VEGFR-2
资金
- Brazilian National Council of Research (CNPq, INCT-INOFAR) [465.249/2014-0]
Vascular endothelial growth factor receptor 2 (VEGFR-2) is a tyrosine kinase that mediates a large number of cell responses associated with angiogenesis. The control of the angiogenic pathway in tumorigenesis by the inhibition of VEGFR-2 is considered a promising therapeutic strategy for the prevention and control of solid tumor growth. In this study, the design, synthesis, and biological evaluation of a novel series of VEGFR-2 inhibitors with anN-acylhydrazone (NAH) scaffold (9a-h) are reported. The molecular design is validated by docking studies and by in vitro inhibitory activity assays. Compounds9b,9c,9d, and9feffectively inhibited neovascularization induced by VEGF in the chorioallantoic membrane assay. Thus, these NAH derivatives are promising antiangiogenic prototypes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据